GSK and SCYNEXIS announce agreement to commercialise and further develop Brexafemme
SCYNEXIS will receive an upfront payment of $90 million with future performance-based milestone payments and tiered royalties
SCYNEXIS will receive an upfront payment of $90 million with future performance-based milestone payments and tiered royalties
The facility is over 79,000 square feet and is equipped with packaging lines
The agreement between Eli Lilly and Janssen was established to allow the two companies to share resources for the goal of accelerating the evaluation of the respective companies’ assets, mirikizumab and Tremfya (guselkumab).
India formulation sales at Rs. 3,391.9 crore, up 7.1% over Q3 last year
Dr. Jain is a biotechnology industry veteran with more than two decades of experience in pharmaceutical development across her time with ChemoCentryx, AbbVie, Abbott Laboratories, and G.D. Searle and Co
Supriya Lifescience Limited has informed that the European Directorate for the Quality of Medicines (EDQM) has granted Attestation of Inspection (EU-GMP) for Lote API Facility, Ratnagiri, Maharashtra.
The companies will leverage their respective proprietary technology platforms
The drug will be manufactured at the group’s formulation manufacturing facility at Ahmedabad SEZ, India
Based on DESTINY-Breast04 results which showed Daiichi Sankyo and AstraZeneca’s ENHERTU reduced risk of disease progression or death by 50% and increased overall survival by more than six months versus chemotherapy
The 562,000 square feet facility has been recognized as the first and largest integrated insulin manufacturer in Malaysia by MBR
Subscribe To Our Newsletter & Stay Updated